[HTML][HTML] Lutathera® Orphans: State of the Art and Future Application of Radioligand Therapy with 177Lu-DOTATATE
Lutathera® is the first EMA-and FDA-approved radiopharmaceutical for radioligand therapy
(RLT). Currently, on the legacy of the NETTER1 trial, only adult patients with progressive …
(RLT). Currently, on the legacy of the NETTER1 trial, only adult patients with progressive …
[HTML][HTML] Positron emission tomography in the diagnosis and follow-up of transthyretin amyloid cardiomyopathy patients: a systematic review
HSA Tingen, A Tubben, JH Van'T Oever… - European journal of …, 2023 - Springer
Purpose Transthyretin (ATTR) amyloidosis is a progressive protein misfolding disease with
frequent cardiac involvement. This review aims to determine the value of PET in diagnosis …
frequent cardiac involvement. This review aims to determine the value of PET in diagnosis …
[HTML][HTML] EANM practice guideline for quantitative SPECT-CT
JC Dickson, IS Armstrong, PM Gabiña… - European journal of …, 2023 - Springer
Abstract Purpose Quantitative SPECT-CT is a modality of growing importance with initial
developments in post radionuclide therapy dosimetry, and more recent expansion into bone …
developments in post radionuclide therapy dosimetry, and more recent expansion into bone …
[HTML][HTML] Relationships between uptake of [68Ga]Ga-DOTA-TATE and absorbed dose in [177Lu]Lu-DOTA-TATE therapy
A Stenvall, J Gustafsson, E Larsson, D Roth… - EJNMMI research, 2022 - Springer
Abstract Background Somatostatin receptor 68Ga PET imaging is standard for evaluation of
a patient's suitability for 177Lu peptide receptor radionuclide therapy of neuroendocrine …
a patient's suitability for 177Lu peptide receptor radionuclide therapy of neuroendocrine …
Prediction of 177Lu-DOTATATE PRRT outcome using multimodality imaging in patients with gastroenteropancreatic neuroendocrine tumors: results from a …
M Mileva, G Marin, H Levillain, C Artigas… - Journal of Nuclear …, 2024 - Soc Nuclear Med
Our objective was to predict the outcome of peptide receptor radionuclide therapy (PRRT)
using multimodality imaging and tumor dosimetry on gastroenteropancreatic …
using multimodality imaging and tumor dosimetry on gastroenteropancreatic …
Development of Highly Potent Clinical Candidates for Theranostic Applications against Cholecystokinin-2 Receptor Positive Cancers
Peptide receptor radionuclide therapy (PRRT) is a promising form of systemic radiation
therapy designed to eradicate cancer. Cholecystokinin-2 receptor (CCK2R) is an important …
therapy designed to eradicate cancer. Cholecystokinin-2 receptor (CCK2R) is an important …
[HTML][HTML] A prospective, randomized, phase II study to assess the schemas of retreatment with Lutathera® in patients with new progression of an intestinal, well …
E Deshayes, E Assenat, L Meignant, M Bardiès… - BMC cancer, 2022 - Springer
Background Although neuroendocrine tumors (NET) are classed as rare, they have a high
prevalence and their incidence is increasing. Effective treatment with lutetium 17-[177Lu] Lu …
prevalence and their incidence is increasing. Effective treatment with lutetium 17-[177Lu] Lu …
A radiomic‐ and dosiomic‐based machine learning regression model for pretreatment planning in 177Lu‐DOTATATE therapy
D Plachouris, V Eleftheriadis, T Nanos… - Medical …, 2023 - Wiley Online Library
Background Standardized patient‐specific pretreatment dosimetry planning is mandatory in
the modern era of nuclear molecular radiotherapy, which may eventually lead to …
the modern era of nuclear molecular radiotherapy, which may eventually lead to …
Impact of single-time-point estimates of 177Lu-PRRT absorbed doses on patient management: validation of a trained multiple-linear-regression model in 159 patients …
A Chicheportiche, M Sason, M Zidan… - Journal of Nuclear …, 2023 - Soc Nuclear Med
Dosimetry after 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) enables
estimation of radiation doses absorbed by normal organs and target lesions. This process is …
estimation of radiation doses absorbed by normal organs and target lesions. This process is …
The predictive value of pretherapy [68Ga]Ga-DOTA-TATE PET and biomarkers in [177Lu]Lu-PRRT tumor dosimetry
A Akhavanallaf, AB Peterson, K Fitzpatrick… - European journal of …, 2023 - Springer
Abstract Purpose Metastatic neuroendocrine tumors (NETs) overexpressing type 2
somatostatin receptors are the target for peptide receptor radionuclide therapy (PRRT) …
somatostatin receptors are the target for peptide receptor radionuclide therapy (PRRT) …